Clinical development of Ebola vaccines.
Clinical development of Ebola vaccines.
复制标题
DOI：
10.1177/2051013615611017
复制
发表时间：
2015-09-01
期刊：
影响因子：
--
通讯作者：
Sridhar, Saranya
中科院分区：
文献类型：
--
作者：
Sridhar, Saranya
西非正在爆发的埃博拉病毒病凸显了缺乏获得许可的药物或疫苗来对抗这种疾病，并再次表明开发埃博拉疫苗的紧迫性。通过评估动物模型的临床前疗效并加快临床开发，正在开发许多不同的疫苗平台。超过 15 种不同的疫苗处于临床前开发阶段，8 种疫苗目前处于不同的临床评估阶段。这些疫苗包括 DNA 疫苗、病毒样颗粒和病毒载体，例如活复制性水泡性口炎病毒 (rVSV)、人类和黑猩猩腺病毒以及牛痘病毒。最近，埃博拉疫苗首次三期试验的初步结果显示，rVSV载体疫苗显示出良好的疗效。这篇综述描绘了这一快速发展的研究领域，重点关注临床开发中的疫苗，并讨论了埃博拉疫苗的许可和部署所面临的未来机遇和挑战。
The ongoing outbreak of Ebola virus disease in West Africa highlighted the lack of a licensed drug or vaccine to combat the disease and has renewed the urgency to develop a pipeline of Ebola vaccines. A number of different vaccine platforms are being developed by assessing preclinical efficacy in animal models and expediting clinical development. Over 15 different vaccines are in preclinical development and 8 vaccines are now in different stages of clinical evaluation. These vaccines include DNA vaccines, virus-like particles and viral vectors such as live replicating vesicular stomatitis virus (rVSV), human and chimpanzee adenovirus, and vaccinia virus. Recently, in preliminary results reported from the first phase III trial of an Ebola vaccine, the rVSV-vectored vaccine showed promising efficacy. This review charts this rapidly advancing area of research focusing on vaccines in clinical development and discusses the future opportunities and challenges faced in the licensure and deployment of Ebola vaccines.